Trial reportMycopathologia2022
Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study.
Trial report in Mycopathologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Secondary fungal infections in severe acute viral diseases: clinical features and underlying immune mechanisms.Frontiers in microbiology · 2026Review
- COVID-19-Associated Mucormycosis: Identifying Mortality Predictors in a Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Clinical characteristics of patients with COVID-19-associated mucormycosis (CAM) hospitalized at Shafa Hospital, Kerman: 2022.BMC infectious diseases · 2025Article
- Epidemiology of mucormycosis in COVID-19 patients in northwest Iran:Current medical mycology · 2025Article
- Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review.JAMA · 2024Review
- Rhinocerebral mucormycosis in immunocompetent patients: a case report and review of literature.Infection · 2024Review
- Comparison Between Pre-COVID and Post-COVID Mucormycosis: A Systematic Review and Meta-analysis.Journal of maxillofacial and oral surgery · 2024Review
- Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.Mycopathologia · 2024Review
- Case report: COVID-19-associated mucormycosis co-infection withFrontiers in medicine · 2023Article
- Foreign body aspiration and mucormycosis: a case report.Frontiers in medicine · 2023Article
- COVID-19, mucormycosis, and the cow: Damned lies!Indian journal of medical microbiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 associated mucormycosis (CAM) has been known as one of the most severe post-COVID morbidities.
objectivesTo describe CAM cases, identify possible risk factors, and report outcomes of patients.
methodsThis retrospective study was performed in Amir-Alam Hospital, Tehran, Iran between February 2020 and September 2021. Patients with mucormycosis who had an active or previous diagnosis of COVID-19 have been included.
resultsOf 94 patients with mucormycosis, 52 (33 men and 19 women; mean age: 57.0 ± 11.82 years) were identified with an active or history of COVID-19. Rhino-orbital, rhino maxillary, rhino-orbito cerebral subtypes of mucormycosis were detected in 6 (11.5%), 18(34.6%), and 28(53.8%) patients. As a control group, 130 (69 men and 61 women; mean age: 53.10 ± 14.49 years) random RT-PCR-confirmed COVID-19 patients without mucormycosis have been included. The mean interval between COVID-19 diagnosis and initial mucormycosis symptoms was 16.63 ± 8.4 days (range 0-51). Those in the CAM group had a significantly more severe course of COVID-19 (OR = 3.60, P-value < 0.01). Known history of previous diabetes mellitus (OR = 7.37, P-value < 0.01), smoking (OR = 4.55, P-value < 0.01), and history of receiving high-dose corticosteroid pulse therapy because of more severe COVID-19 (P-value = 0.022) were found as risk factors. New-onset post-COVID hyperglycemia was lower in the CAM group (46.2% vs. 63.8%; OR = 0.485, P-value = 0.028). After treatment of the CAM group, 41(78.8%) of patients recovered from mucormycosis. The mean ages of the expired patients in the CAM group were significantly higher than those who recovered from mucormycosis (66.18 ± 9.56 vs. 54.56 ± 11.22 years; P < 0.01); and COVID-19 disease was more severe (P = 0.046).
conclusionEither active or history of COVID-19 can cause an increase in the risk of mucormycosis development. Some of the most important risk factors are the medical history of diabetes mellitus, smoking, and high-dose corticosteroid therapy. CAM is important possible comorbidity related to COVID-19, which could make the post-COVID conditions more complicated. More research and studies with greater sample sizes among different ethnicities are needed to explore the association between COVID-19 and mucormycosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.